Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BioGaia AB ( ($SE:BIOG.B) ) has shared an update.
BioGaia has launched Prodentis® FRESH BREATH, a probiotic lozenge designed to promote fresh breath and support oral health by combining zinc and patented probiotics. This product enhances BioGaia’s oral care portfolio and positions the company at the forefront of science-backed solutions for oral health, addressing the global demand for natural and effective oral care products.
The most recent analyst rating on ($SE:BIOG.B) stock is a Buy with a SEK115.00 price target. To see the full list of analyst forecasts on BioGaia AB stock, see the SE:BIOG.B Stock Forecast page.
More about BioGaia AB
BioGaia is a Swedish probiotics company with over 35 years of experience in microbiome research. It develops, markets, and sells probiotic products focused on gut, immune, and oral health, operating in over 100 markets globally. BioGaia’s class B share is listed on the Mid Cap segment of Nasdaq Stockholm.
Average Trading Volume: 166,172
Technical Sentiment Signal: Strong Buy
Current Market Cap: SEK10.9B
For detailed information about BIOG.B stock, go to TipRanks’ Stock Analysis page.